Abstract
Heat shock protein 90 (Hsp90) plays a vital role in the progress of malignant disease and elevated Hsp90 expression has been reported in pancreatic cancer. In this study, we radiolabeled a dimeric Sansalvamide A derivative (Di-San A1) with 64Cu, and evaluated the feasibility of using 64Cu-Di-San A1 for PET imaging of Hsp90 expression in a mouse model of pancreatic cancer. A macrocyclic chelator NOTA (1,4,7-triazacyclononane-1,4,7-trisacetic acid) was conjugated to Di-San A1. 64Cu-Di-San A1 was successfully prepared in a radiochemical yield > 97% with a radiochemical purity > 98%. 64Cu-Di-San A1 is stable in PBS and mouse serum with > 92% of parent probe intact after 4 h incubation. The cell binding and uptake revealed that 64Cu-Di-San A1 binds to Hsp90-positive PL45 pancreatic cancer cells, and the binding can be effectively blocked by an Hsp90 inhibitor (17AAG). For microPET study, 64Cu-Di-San A1 shows good in vivo performance in terms of tumor uptake in nude mice bearing PL45 tumors. The Hsp90-specific tumor activity accumulation of 64Cu-Di-San A1 was further demonstrated by significant reduction of PL45 tumor uptake with a pre-injected blocking dose of 17AAG. The ex vivo PET imaging and biodistribution results were consistent with the quantitative analysis of PET imaging, demonstrating good tumor-to-muscle ratio (5.35 ± 0.46) of 64Cu-Di-San A1 at 4 h post-injection in PL45 tumor mouse xenografts. 64Cu-Di-San A1 allows PET imaging of Hsp90 expression in PL45 tumors, which may provide a non-invasive method to quantitatively characterize Hsp90 expression in pancreatic cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alauddin MM, De Palatis L (2015) Current and future trends in early detection of pancreatic cancer: molecular targets and PET probes. Curr Med Chem 22:3370–3389
Alexander LD, Sellers RP, Davis MR, Ardi VC, Johnson VA, Vasko RC, McAlpine SR (2009) Evaluation of di-sansalvamide A derivatives: synthesis, structure-activity relationship, and mechanism of action. J Med Chem 52:7927–7930. https://doi.org/10.1021/jm901566c
Barrott JJ, Haystead TA (2013) Hsp90, an unlikely ally in the war on cancer. FEBS J 280:1381–1396. https://doi.org/10.1111/febs.12147
Belofsky GN, Jensen PR, Fenical W (1999) Sansalvamide: a new cytotoxic cyclic depsipeptide produced by a marine fungus of the genus Fusarium. Tetrahedron Lett 40:2913–2916
Blanco VM, Latif T, Chu Z, Qi X (2015) Imaging and therapy of pancreatic cancer with phosphatidylserine-targeted nanovesicles. Transl Oncol 8:196–203. https://doi.org/10.1016/j.tranon.2015.03.011
Cai H, Li Z, Huang CW, Park R, Shahinian AH, Conti PS (2010a) An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals. Nucl Med Biol 37:57–65. https://doi.org/10.1016/j.nucmedbio.2009.09.001
Cai H, Li Z, Huang CW, Shahinian AH, Wang H, Park R, Conti PS (2010b) Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression. Bioconjug Chem 21:1417–1424. https://doi.org/10.1021/bc900537f
Carroll CL, Johnston JV, Kekec A, Brown JD, Parry E, Cajica J, Medina I, Cook KM, Corral R, Pan PS, McAlpine SR (2005) Synthesis and cytotoxicity of novel sansalvamide A derivatives. Org Lett 7:3481–3484. https://doi.org/10.1021/ol051161g
Chen X (2006) Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem 6:227–234
Chen K, Chen X (2011) Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol 38:70–86
Chen K, Conti PS (2010) Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 62:1005–1022. https://doi.org/10.1016/j.addr.2010.09.004
Chen K, Sun X, Niu G, Ma Y, Yap LP, Hui X, Wu K, Fan D, Conti PS, Chen X (2012a) Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature. Mol Imaging Biol 14:96–105. https://doi.org/10.1007/s11307-011-0479-1
Chen K, Wang X, Lin WY, Shen CK, Yap LP, Hughes LD, Conti PS (2012b) Strain-promoted catalyst-free click chemistry for rapid construction of 64Cu-labeled PET imaging probes. ACS Med Chem Lett 3:1019–1023. https://doi.org/10.1021/ml300236m
Chen K, Ma W, Li G, Wang J, Yang W, Yap LP, Hughes LD, Park R, Conti PS (2013) Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for microPET imaging of CD13 receptor expression. Mol Pharm 10:417–427. https://doi.org/10.1021/mp3005676
Davis MR, Styers TJ, Rodriguez RA, Pan PS, Vasko RC, McAlpine SR (2008) Synthesis and cytotoxicity of a new class of potent decapeptide macrocycles. Org Lett 10:177–180. https://doi.org/10.1021/ol702403r
Hao G, Singh AN, Oz OK, Sun X (2011) Recent advances in copper radiopharmaceuticals. Curr Radiopharm 4:109–121. CRP-4-2-109
Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M (2001) Noninvasive imaging of alphavbeta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781–1785
Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617. https://doi.org/10.1056/NEJMra0901557
Huang R, Wang M, Zhu Y, Conti PS, Chen K (2015) Development of PET probes for cancer imaging. Curr Top Med Chem 15:795–819
Jackson IM, Scott PJH, Thompson S (2017) Clinical applications of radiolabeled peptides for PET. Semin Nucl Med 47:493–523. https://doi.org/10.1053/j.semnuclmed.2017.05.007
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP (2016) Pancreatic cancer. Nat Rev Dis Primers 2:16022. https://doi.org/10.1038/nrdp.2016.22
Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, Stoeltzing O (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13:6459–6468. https://doi.org/10.1158/1078-0432.ccr-07-1104
Li G, Wang X, Zong S, Wang J, Conti PS, Chen K (2014) MicroPET imaging of CD13 expression using a 64Cu-labeled dimeric NGR peptide based on sarcophagine cage. Mol Pharm 11:3938–3946. https://doi.org/10.1021/mp500354x
Liu S, Gu W, Lo D, Ding XZ, Ujiki M, Adrian TE, Soff GA, Silverman RB (2005) N-methylsansalvamide a peptide analogues. Potent new antitumor agents. J Med Chem 48:3630–3638. https://doi.org/10.1021/jm048952t
Ma MT, Donnelly PS (2011) Peptide targeted copper-64 radiopharmaceuticals. Curr Top Med Chem 11:500–520
Matsuoka L, Selby R, Genyk Y (2012) The surgical management of pancreatic cancer. Gastroenterol Clin North Am 41:211–221. https://doi.org/10.1016/j.gtc.2011.12.015
Miao Y, Quinn TP (2007) Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front Biosci 12:4514–4524
Miyata Y, Nakamoto H, Neckers L (2013) The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 19:347–365
Nipp R, Tramontano AC, Kong CY, Pandharipande P, Dowling EC, Schrag D, Hur C (2018) Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med 7:525–535. https://doi.org/10.1002/cam4.1277
Niu G, Chen X (2009) From protein-protein interaction to therapy response: molecular imaging of heat shock proteins. Eur J Radiol 70:294–304. https://doi.org/10.1016/j.ejrad.2009.01.052
Niu G, Cai W, Chen K, Chen X (2008) Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor. Mol Imaging Biol 10:99–106. https://doi.org/10.1007/s11307-007-0123-2
Niu G, Li Z, Cao Q, Chen X (2009) Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging 36:1510–1519. https://doi.org/10.1007/s00259-009-1158-1
Ogata M, Naito Z, Tanaka S, Moriyama Y, Asano G (2000) Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 67:177–185
Otrubova K, Lushington G, Vander Velde D, McGuire KL, McAlpine SR (2008) Comprehensive study of sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines. J Med Chem 51:530–544. https://doi.org/10.1021/jm070731a
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–2921. https://doi.org/10.1158/0008-5472.can-14-0155
Raman SP, Chen Y, Fishman EK (2015) Cross-sectional imaging and the role of positron emission tomography in pancreatic cancer evaluation. Semin Oncol 42:40–58. https://doi.org/10.1053/j.seminoncol.2014.12.005
Romans-Fuertes P, Sondergaard TE, Sandmann MI, Wollenberg RD, Nielsen KF, Hansen FT, Giese H, Brodersen DE, Sorensen JL (2016) Identification of the non-ribosomal peptide synthetase responsible for biosynthesis of the potential anti-cancer drug sansalvamide in Fusarium solani. Curr Genet 62:799–807
Sellers RP, Alexander LD, Johnson VA, Lin CC, Savage J, Corral R, Moss J, Slugocki TS, Singh EK, Davis MR, Ravula S, Spicer JE, Oelrich JL, Thornquist A, Pan CM, McAlpine SR (2010) Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives. Bioorg Med Chem 18:6822–6856. https://doi.org/10.1016/j.bmc.2010.07.042
Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S (2009) Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem 20:750–759. https://doi.org/10.1021/bc800455p
Shokeen M, Anderson CJ (2009) Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res 42:832–841. https://doi.org/10.1021/ar800255q
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387
Soga S, Akinaga S, Shiotsu Y (2013) Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des 19:366–376
Solit DB, Chiosis G (2008) Development and application of Hsp90 inhibitors. Drug Discov Today 13:38–43. https://doi.org/10.1016/j.drudis.2007.10.007
Sugyo A, Tsuji AB, Sudo H, Nagatsu K, Koizumi M, Ukai Y, Kurosawa G, Zhang MR, Kurosawa Y, Saga T (2013) Evaluation of 89Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer. PLoS ONE 8:e61230. https://doi.org/10.1371/journal.pone.0061230
Sun X, Wuest M, Weisman GR, Wong EH, Reed DP, Boswell CA, Motekaitis R, Martell AE, Welch MJ, Anderson CJ (2002) Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem 45:469–477
Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537–549. https://doi.org/10.1038/nrc2887
Ujiki MB, Milam B, Ding XZ, Roginsky AB, Salabat MR, Talamonti MS, Bell RH, Gu W, Silverman RB, Adrian TE (2006) A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochem Biophys Res Commun 340:1224–1228. https://doi.org/10.1016/j.bbrc.2005.12.131
van de Ven SM, Elias SG, Chan CT, Miao Z, Cheng Z, De A, Gambhir SS (2012) Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model. Clin Cancer Res 18:1073–1081. https://doi.org/10.1158/1078-0432.ccr-10-3213
Wang H, Li D, Liu S, Liu R, Yuan H, Krasnoperov V, Shan H, Conti PS, Gill PS, Li Z (2015) Small-animal PET imaging of pancreatic cancer xenografts using a 64Cu-labeled monoclonal antibody, MAb159. J Nucl Med 56:908–913. https://doi.org/10.2967/jnumed.115.155812
Wong DS, Jay DG (2016) Chapter 6—emerging roles of extracellular Hsp90 in Cancer. In: Jennifer I, Luke W (eds) Advances in cancer research, vol 129. Academic Press, pp 141–163. https://doi.org/10.1016/bs.acr.2016.01.001
Zhu D, Wang L, Zhang H, Chen J, Wang Y, Byanju S, Liao M (2017) Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: a systematic review and meta-analysis. Medicine 96:e7813. https://doi.org/10.1097/md.0000000000007813
Acknowledgements
This work was supported by the USC Department of Radiology and the International S&T Cooperation Program of China (2015DFA31650).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in this study involving animals were in accordance with the ethical standards of the University of Southern California Institutional Animal Care and Use Committee.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Handling Editor: G. J. Peters.
Rights and permissions
About this article
Cite this article
Wang, X., Zhang, J., Wu, H. et al. PET imaging of Hsp90 expression in pancreatic cancer using a new 64Cu-labeled dimeric Sansalvamide A decapeptide. Amino Acids 50, 897–907 (2018). https://doi.org/10.1007/s00726-018-2566-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-018-2566-y